Biological E, Takeda join hands to accelerate access to Dengue Vaccine in endemic areas Ruchika Sharma29 Feb 2024 3:00 PM ISTHyderabad: Takeda and Biological E. Limited (BE), an India-based Vaccines and Pharmaceutical Company, has announced a strategic partnership...
FDA approves budesonide oral suspension for treatment of eosinophilic esophagitis Dr. Kamal Kant Kohli14 Feb 2024 10:00 AM ISTThe Food and Drug Administration (FDA) has approved EOHILIA (budesonide) oral suspension for treatment of eosinophilic esophagitis among adults and...
Takeda Eohilia gets USFDA nod for people aged 11 years and older with eosinophilic esophagitis Ruchika Sharma13 Feb 2024 1:30 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and...
Takeda Hyqvia gets USFDA nod for Chronic Inflammatory Demyelinating Polyneuropathy Ruchika Sharma17 Jan 2024 3:54 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA [Immune Globulin Infusion 10% (Human) with...
Takeda gets Chinese nod for Livtencity for adults with Post-transplant Cytomegalovirus Refractory to prior therapies Ruchika Sharma26 Dec 2023 10:00 AM ISTOsaka: Takeda has announced that LIVTENCITY (maribavir) has been approved by the National Medical Products Administration (NMPA) of China...
USFDA approves Takeda Fruzaqla for previously treated Metastatic Colorectal Cancer Ruchika Sharma10 Nov 2023 1:51 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for...
FIRST: Takeda gets USFDA nod for Adzybm for rare inherited Blood Clotting Disorder Ruchika Sharma10 Nov 2023 11:39 AM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the...
Failed Drugs, Loss of Patent: Japanese drugmaker Takeda slashes full-year profit forecast by 36 percent Ruchika Sharma26 Oct 2023 3:21 PM ISTTokyo: Japan's biggest drugmaker Takeda Pharmaceutical has slashed its full-year profit forecast by 36% as it contends with disappointments in...
Takeda to voluntary withdraw lung cancer therapy Exkivity Ruchika Sharma4 Oct 2023 4:30 PM ISTOsaka: Takeda has announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA...
Takeda gets USFDA nod for subcutaneous administration of Entyvio for ulcerative colitis Ruchika Sharma29 Sept 2023 12:30 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO...
USFDA accepts BLA for subcutaneous administration of Takeda Entyvio for maintenance therapy in Crohn's Disease Ruchika Sharma14 Sept 2023 3:58 PM ISTOsaka: Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA)...
ImmunoGen, Takeda ink pact to develop, commercialize Elahere in Japan Ruchika Sharma30 Aug 2023 1:00 PM ISTPer the agreement, ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan.
